-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA Evaluating The Need For Regulatory Action In Argenx's Vyvgart Hytrulo After Reports Of Severe Worsening Of Chronic Inflammatory Demyelinating Polyradiculoneuropathy In CIDP Patients

Benzinga·06/30/2025 15:39:42
Listen to the news